BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hernández-Conde M, Fernández I, Perelló C, Gallego A, Bonacci M, Pascasio JM, Romero-Gómez M, Llerena S, Fernández-Rodríguez C, Castro Urda JL, García Buey L, Carmona I, Morillas RM, García ND, Gea F, Carrión JA, Castellote J, Moreno-Planas JM, Piqueras Alcol B, Molina E, Diago M, Montoliu S, de la Vega J, Menéndez F, Sánchez Ruano JJ, García-Samaniego J, Rosales-Zabal JM, Anton MD, Badia E, Souto-Rodríguez R, Salmeron FJ, Fernández-Bermejo M, Figueruela B, Moreno-Palomares JJ, Calleja JL. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort. J Viral Hepat 2019;26:55-64. [PMID: 30265418 DOI: 10.1111/jvh.13008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Asselah T, Zeuzem S, Reau N, Hwang P, Long J, Talwani R, Robertson MN, Haber BA. Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis. Curr Med Res Opin 2020;36:1325-32. [PMID: 32459122 DOI: 10.1080/03007995.2020.1775075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
2 Hinrichsen H, Stoehr A, Cornberg M, Klinker H, Heyne R, John C, Simon KG, Guenther V, Martin K, Witte V, Zeuzem S. Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry. Eur J Gastroenterol Hepatol 2021;33:415-23. [PMID: 32345848 DOI: 10.1097/MEG.0000000000001759] [Reference Citation Analysis]
3 Cheng P, Chen C, Yu M, Lin C, Lin C, Peng C, Tseng K, Lo C, Tseng I, Liu C. Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan. Journal of Microbiology, Immunology and Infection 2021;54:588-95. [DOI: 10.1016/j.jmii.2020.05.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Wang SJ, Huang CF, Yu ML. Elbasvir and grazoprevir for the treatment of hepatitis C. Expert Rev Anti Infect Ther 2021;19:1071-81. [PMID: 33428488 DOI: 10.1080/14787210.2021.1874351] [Reference Citation Analysis]
5 Dietz J, Vermehren J, Matschenz K, Buggisch P, Klinker H, Schulze Zur Wiesch J, Hinrichsen H, Peiffer KH, Graf C, Discher T, Trauth J, Schattenberg JM, Piecha F, Mauss S, Niederau C, Müller T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions. Liver Int 2020. [PMID: 32640072 DOI: 10.1111/liv.14591] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 González-Colominas E, Batlle M, Monge-Escartín I, Duran X, Viu A, de Antonio-Cuscó M, Grau S, Bessa X, Carrión JA. Impact of HCV cure with drug-acting antivirals in the use of concomitant medication and lipid profile: follow-up data 2 years after the sustained virological response. Eur J Gastroenterol Hepatol 2021;32:214-22. [PMID: 32195695 DOI: 10.1097/MEG.0000000000001714] [Reference Citation Analysis]
7 Hsieh YC, Lin CL, Hung CH, Chen CH, Tung SY, Lin CY, Hu TH, Lu SN, Chien RN, Sheen IS. Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects. J Viral Hepat 2020;27:505-13. [PMID: 32039536 DOI: 10.1111/jvh.13262] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Jang ES, Kim KA, Kim YS, Kim IH, Lee BS, Lee YJ, Chung WJ, Jeong SH. Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study. Korean J Intern Med 2021;36:S1-8. [PMID: 32539296 DOI: 10.3904/kjim.2019.357] [Reference Citation Analysis]
9 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
10 Puenpatom A, Cao Y, Yu X, Kanwal F, El-Serag HB, Kramer JR. Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection. Infect Dis Ther. 2020;9:355-365. [PMID: 32297307 DOI: 10.1007/s40121-020-00293-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zarębska‐michaluk D, Jaroszewicz J, Buczyńska I, Simon K, Lorenc B, Tudrujek‐zdunek M, Tomasiewicz K, Sitko M, Garlicki A, Janczewska E, Dybowska D, Halota W, Pawłowska M, Pabjan P, Mazur W, Czauż‐andrzejuk A, Berak H, Horban A, Socha Ł, Klapaczyński J, Piekarska A, Blaszkowska M, Belica‐wdowik T, Dobracka B, Tronina O, Deroń Z, Białkowska‐warzecha J, Laurans Ł, Flisiak R. Real‐world experience with Grazoprevir/Elbasvir in the treatment of previously “difficult to treat” patients infected with hepatitis C virus genotype 1 and 4. Journal of Gastroenterology and Hepatology 2020;35:1238-46. [DOI: 10.1111/jgh.14936] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Drysdale K, Ntuli Y, Bestwick J, Gelson W, Agarwal K, Forton D, Mutimer D, Elsharkawy AM, Townley C, Mahomed F, Foster GR. English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed. Aliment Pharmacol Ther 2020;52:168-81. [PMID: 32441382 DOI: 10.1111/apt.15780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Huang CF, Hung CH, Cheng PN, Bair MJ, Huang YH, Kao JH, Hsu SJ, Lee PL, Chen JJ, Chien RN, Peng CY, Lin CY, Hsieh TY, Cheng CH, Dai CY, Huang JF, Chuang WL, Yu ML. An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions. J Infect Dis 2019;220:557-66. [PMID: 30957170 DOI: 10.1093/infdis/jiz154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]